Early research indicate that the compound – a dual agonist of incretin and GIP receptors – presents a substantial improvement in weight management programs . Beyond existing therapies, this dual-action compound seems to modify food intake and metabolic utilization through distinct mechanisms . Although additional investigation is required , th